The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 10, 2012, Pages 3498-3502

  Furet, Pascal ^a   Chène, Patrick ^a   De Pover, Alain ^a   Valat, Thérèse Stachyra ^a   Lisztwan, Joanna Hergovich ^a   Kallen, Joerg ^a   Masuya, Keiichi ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anticancer agents; p53 MDM2 inhibitors; Protein protein interaction inhibitors; Structure based design

Indexed keywords

PROTEIN MDM2; PROTEIN P53; VALINE;

ARTICLE; CANCER THERAPY; CRYSTAL STRUCTURE; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS;

MODELS, MOLECULAR; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; VALINE;

EID: 84860469117     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.03.083     Document Type: Article

References (17)

1. P. Chène Nat. Rev. Cancer 3 2003 102
2. For recent reviews see: M. Millard, D. Pathania, F. Grande, S. Xu, and N. Neamati Curr. Pharm. Des. 17 2011 536
3. C.J. Brown, C.F.Cheok, C.S. Verma, and D.P. Lane Trends Pharmacol. Sci. 32 2011 53
4. Wang, W.; Hu, Y. Med. Res. Rev. 2011, doi: 10. 1002/med.20236.
5. B.T. Vu, and L. Vassilev L. Vassilev, D. Fry, Current Topics in Micriobiology and Immunology (Small Molecules Inhibitors of Protein-Protein Interactions) Vol. 348 2011 Springer Berlin, Heidelberg 151 172
6. L. Weber Expert Opin. Ther. Patents 20 2010 179
7. S. Shangary, and S. Wang Ann. Rev. Pharmacol. Toxicol. 49 2009 223
8. C.F. Cheok, C.S. Verma, J. Baselga, and D.P. Lane Nat. Rev. Clin. Oncol. 8 2011 25
9. P.H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A.J. Levine, and N.P. Pavletich Science 274 1996 948 (PDB code: 1YCR)
10. C. García-Echeverría, P. Chène, M.J.J. Blommers, and P. Furet J. Med. Chem. 43 2000 3205
11. P. Chène, J. Fuchs, C. Bohn, C. García-Echeverría, P. Furet, and D. Fabbro J. Mol. Biol. 299 2000 245
12. P. Chène, J. Fuchs, I. Carena, P. Furet, and C. García-Echeverría FEBS Lett. 529 2002 293
13. 2O/GBSA force field.
14. 50 values given are means of at least three measurements
15. The synthesis of the compounds is described in: Boettcher, A.; Buschmann, N.; Furet, P.; Groell, J. M.; Kallen, J.; Hergovich Lisztwan, J.; Masuya, K.; Mayr, L.; Vaupel, A. PCT Int. Appl. WO 2008119741, 2008; Chem. Abstr. 2008, 149, 448395.
16. Kallen, J., et al. The details of this X-ray structure determination will be published elsewhere. The coordinates have been deposited with PDB ID code 4DIJ. This crystal structure is in agreement with the crystallographic studies published in Ref. 16. In this article, the authors have selected a potent compound from our patent application published in 2008 (Ref. 12), resynthesized it and used it for X-ray studies with MDM2 and MDM4.
17. G.M. Popowicz, A. Czarna, S. Wolf, W. Wang, A. Doemling, and T.A. Holak Cell Cycle 9 2010 1104